Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Identifieur interne : 002F09 ( Ncbi/Merge ); précédent : 002F08; suivant : 002F10Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Auteurs : Estelle Dellapina [France] ; Angélique Gerdelat-Mas ; Fabienne Ory-Magne ; Laure Pourcel ; Monique Galitzky ; Fabienne Calvas ; Marion Simonetta-Moreau ; Claire Thalamas ; Pierre Payoux ; Christine Brefel-CourbonSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2011.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Apomorphine (pharmacology), Apomorphine (therapeutic use), Cerebral Cortex (radionuclide imaging), Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia (diagnosis), Neuralgia (etiology), Oxygen Isotopes (diagnostic use), Pain Threshold (drug effects), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease (radionuclide imaging), Positron-Emission Tomography (methods).
- MESH :
- chemical , diagnostic use : Oxygen Isotopes.
- chemical , pharmacology : Antiparkinson Agents, Apomorphine.
- chemical , therapeutic use : Antiparkinson Agents, Apomorphine.
- complications : Parkinson Disease.
- diagnosis : Neuralgia.
- drug effects : Pain Threshold.
- drug therapy : Parkinson Disease.
- etiology : Neuralgia.
- methods : Positron-Emission Tomography.
- pathology : Parkinson Disease.
- radionuclide imaging : Cerebral Cortex, Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged.
Abstract
Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H(2)(15)O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved.
DOI: 10.1002/mds.23406
PubMed: 20960436
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001508
- to stream PubMed, to step Curation: 001508
- to stream PubMed, to step Checkpoint: 001472
Links to Exploration step
pubmed:20960436Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.</title><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name><affiliation wicri:level="1"><nlm:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France. estelle.dellapina@inserm.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Gerdelat Mas, Angelique" sort="Gerdelat Mas, Angelique" uniqKey="Gerdelat Mas A" first="Angélique" last="Gerdelat-Mas">Angélique Gerdelat-Mas</name></author><author><name sortKey="Ory Magne, Fabienne" sort="Ory Magne, Fabienne" uniqKey="Ory Magne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name></author><author><name sortKey="Pourcel, Laure" sort="Pourcel, Laure" uniqKey="Pourcel L" first="Laure" last="Pourcel">Laure Pourcel</name></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name></author><author><name sortKey="Calvas, Fabienne" sort="Calvas, Fabienne" uniqKey="Calvas F" first="Fabienne" last="Calvas">Fabienne Calvas</name></author><author><name sortKey="Simonetta Moreau, Marion" sort="Simonetta Moreau, Marion" uniqKey="Simonetta Moreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1002/mds.23406</idno><idno type="RBID">pubmed:20960436</idno><idno type="pmid">20960436</idno><idno type="wicri:Area/PubMed/Corpus">001508</idno><idno type="wicri:Area/PubMed/Curation">001508</idno><idno type="wicri:Area/PubMed/Checkpoint">001472</idno><idno type="wicri:Area/Ncbi/Merge">002F09</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.</title><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name><affiliation wicri:level="1"><nlm:affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France. estelle.dellapina@inserm.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Gerdelat Mas, Angelique" sort="Gerdelat Mas, Angelique" uniqKey="Gerdelat Mas A" first="Angélique" last="Gerdelat-Mas">Angélique Gerdelat-Mas</name></author><author><name sortKey="Ory Magne, Fabienne" sort="Ory Magne, Fabienne" uniqKey="Ory Magne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name></author><author><name sortKey="Pourcel, Laure" sort="Pourcel, Laure" uniqKey="Pourcel L" first="Laure" last="Pourcel">Laure Pourcel</name></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name></author><author><name sortKey="Calvas, Fabienne" sort="Calvas, Fabienne" uniqKey="Calvas F" first="Fabienne" last="Calvas">Fabienne Calvas</name></author><author><name sortKey="Simonetta Moreau, Marion" sort="Simonetta Moreau, Marion" uniqKey="Simonetta Moreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Apomorphine (pharmacology)</term><term>Apomorphine (therapeutic use)</term><term>Cerebral Cortex (radionuclide imaging)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuralgia (diagnosis)</term><term>Neuralgia (etiology)</term><term>Oxygen Isotopes (diagnostic use)</term><term>Pain Threshold (drug effects)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Positron-Emission Tomography (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Oxygen Isotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neuralgia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Pain Threshold</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Neuralgia</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Cerebral Cortex</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H(2)(15)O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20960436</PMID><DateCreated><Year>2011</Year><Month>02</Month><Day>15</Day></DateCreated><DateCompleted><Year>2011</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.</ArticleTitle><Pagination><MedlinePgn>153-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23406</ELocationID><Abstract><AbstractText>Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H(2)(15)O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved.</AbstractText><CopyrightInformation>Copyright © 2010 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dellapina</LastName><ForeName>Estelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Inserm, Imagerie cérébrale et handicaps neurologiques, Toulouse, France. estelle.dellapina@inserm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerdelat-Mas</LastName><ForeName>Angélique</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ory-Magne</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pourcel</LastName><ForeName>Laure</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Galitzky</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Calvas</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Simonetta-Moreau</LastName><ForeName>Marion</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thalamas</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Payoux</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010103">Oxygen Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002540">Cerebral Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009437">Neuralgia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010103">Oxygen Isotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017288">Pain Threshold</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2010</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23406</ArticleId><ArticleId IdType="pubmed">20960436</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><name sortKey="Calvas, Fabienne" sort="Calvas, Fabienne" uniqKey="Calvas F" first="Fabienne" last="Calvas">Fabienne Calvas</name><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name><name sortKey="Gerdelat Mas, Angelique" sort="Gerdelat Mas, Angelique" uniqKey="Gerdelat Mas A" first="Angélique" last="Gerdelat-Mas">Angélique Gerdelat-Mas</name><name sortKey="Ory Magne, Fabienne" sort="Ory Magne, Fabienne" uniqKey="Ory Magne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><name sortKey="Pourcel, Laure" sort="Pourcel, Laure" uniqKey="Pourcel L" first="Laure" last="Pourcel">Laure Pourcel</name><name sortKey="Simonetta Moreau, Marion" sort="Simonetta Moreau, Marion" uniqKey="Simonetta Moreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></noCountry><country name="France"><noRegion><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F09 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002F09 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:20960436
|texte= Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:20960436" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |